The Heart Failure Optimization Study (HF-OPT): rationale and design

R Sanchez1, D Duncker2, B Colley3

  • 1HCA Florida Heart Institute, St. Petersburg, FL, USA.

Insights

This study evaluates left ventricular function recovery in heart failure patients after 3 months of optimal medical therapy. Results may influence decisions on implantable cardioverter-defibrillator implantation for primary prevention.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Medical Device Technology

Background:

  • Current guidelines recommend delaying implantable cardioverter-defibrillator (ICD) implantation for primary prevention in heart failure with reduced ejection fraction (HFrEF) until optimal guideline-directed medical therapy (GDMT) is achieved for at least 3 months.
  • Optimizing GDMT can extend beyond the initial 3-month period, necessitating further evaluation of cardiac function recovery.
  • The Heart Failure Optimization Study (HF-OPT) addresses the need to understand left ventricular function recovery beyond this initial 3-month timeframe in newly diagnosed HFrEF patients.

Purpose of the Study:

  • To assess the recovery of left ventricular ejection fraction (LVEF) in patients with newly diagnosed HFrEF.
  • To evaluate the rate of LVEF improvement beyond 3 months of optimized GDMT.
  • To determine if LVEF can recover to >35% between 90 and 180 days post-diagnosis.

Main Methods:

  • The HF-OPT is a multicenter study with two non-randomized phases: a registry and a study phase.
  • Patients receive a wearable cardioverter-defibrillator (WCD) for the first 90 days and are enrolled in a pre-study registry.
  • Eligible patients undergo LVEF reassessment at 90, 180, and 360 days post-discharge. Approximately 600 subjects are planned for the study portion.

Main Results:

  • The primary objective is to measure the rate of LVEF recovery to >35% between 90 and 180 days.
  • Secondary endpoints include monitoring all-cause mortality and analyzing data from the WCD regarding arrhythmias and shocks.
  • Approximately one-third of the ~600 enrolled subjects are expected to have reduced LVEF at the start of the study phase (day 90).

Conclusions:

  • The HF-OPT study will provide crucial data on LVEF recovery rates between 90 and 180 days in HFrEF patients undergoing GDMT titration.
  • Findings may inform clinical decisions regarding the timing and necessity of primary prophylactic ICD implantation.
  • Understanding functional recovery is key to refining treatment strategies for HFrEF.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
22
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
31
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
130